Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.

Cosmos Health Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CHICAGO, OCT. 13, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS PURCHASED AN ADDITIONAL $300,000 WORTH OF ETHEREUM (ETH), INCREASING ITS TOTAL INVESTMENT IN ETH TO $1.8 MILLION.

COSMOS HEALTH PURCHASES AN ADDITIONAL $300,000 IN ETHEREUM UNDER ITS $300 MILLION DIGITAL ASSETS FACILITY; TOTAL INVESTMENT REACHES $1.8 MILLION

CHICAGO, OCT. 10, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS PURCHASED AN ADDITIONAL $500,000 WORTH OF ETHEREUM (ETH), BRINGING ITS TOTAL INVESTMENT IN ETH TO $1.5 MILLION.

COSMOS HEALTH PURCHASES AN ADDITIONAL $500,000 IN ETHEREUM PURSUANT TO ITS $300 MILLION DIGITAL ASSETS FACILITY

CHICAGO, OCT. 03, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM), A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP,TODAY ANNOUNCED THAT ITS SUBSIDIARY, SKYPHARM S.A., HAS ENTERED INTO AN EXCLUSIVE DISTRIBUTION AGREEMENT, DATED AS OF SEPTEMBER 28, 2025, WITH DIYAR UNITED FOR THE MARKETING AND SALE OF ITS SKY PREMIUM LIFE LINE OF NUTRACEUTICALS IN KUWAIT.

COSMOS HEALTH EXPANDS SKY PREMIUM LIFE INTO $1BN+ KUWAIT MARKET; SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH DIYAR UNITED AND SECURES INITIAL PURCHASE ORDER OF OVER 65,000 UNITS

CHICAGO, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT ITS CHIEF EXECUTIVE OFFICER, GREG SIOKAS, HAS ISSUED THE FOLLOWING LETTER TO THE COMPANY'S SHAREHOLDERS.

COSMOS HEALTH CEO ISSUES LETTER TO SHAREHOLDERS: BUILDING A GLOBAL HEALTHCARE POWERHOUSE WITH $300M DIGITAL FINANCING FACILITY, U.S. MANUFACTURING EXPANSION, AND AI INNOVATION

CHICAGO, SEPT. 25, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. (COSMOS HEALTH OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT ITS WHOLLY OWNED SUBSIDIARY, CANA LABORATORIES S.A.

COSMOS HEALTH EXPANDS ORDER BOOK WITH CONTRACT MANUFACTURING AGREEMENT WITH MEDICAL PHARMAQUALITY S.A. FOR 3 MILLION MYCOFAGYL PESSARIES ANNUALLY

CHICAGO, SEPT. 22, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THE COMMENCEMENT OF ITS U.S. OPERATIONS WITH THE LAUNCH OF ITS PROPRIETARY SKY PREMIUM LIFE FOOD SUPPLEMENTS BRAND.

COSMOS HEALTH COMMENCES U.S. OPERATIONS, ENTERING $164B NUTRACEUTICALS MARKET WITH ITS SKY PREMIUM LIFE BRAND; EXPECTS 75% GROSS MARGINS AND STRONG CASH FLOW, WITH NOOR COLLAGEN ALONE PROJECTED TO GENERATE OVER $12M IN ANNUALIZED REVENUE

COSMOS HEALTH SIGNS DISTRIBUTION DEAL WITH SCIENTIFIC PHARMACY TO LAUNCH SKY PREMIUM LIFE IN OMAN, INCLUDING AN INITIAL ORDER OF 42,000 SUPPLEMENT UNITS.

COSMOS HEALTH EXPANDS PRESENCE IN THE $7 BILLION GCC NUTRACEUTICALS MARKET, SIGNS DISTRIBUTION AGREEMENT WITH SCIENTIFIC PHARMACY FOR SKY PREMIUM LIFE IN OMAN, INCLUDING INITIAL PURCHASE ORDER OF 42,000 UNITS

CHICAGO, AUG. 18, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY'') (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, ANNOUNCED TODAY ITS FINANCIAL RESULTS FOR THE SECOND QUARTER AND SIX-MONTH PERIOD ENDED JUNE 30, 2025. FINANCIAL HIGHLIGHTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 INCOME STATEMENT COSMOS HEALTH CONTINUED ITS POSITIVE TRAJECTORY IN Q2 2025, DELIVERING DOUBLE-DIGIT REVENUE GROWTH OF 11.66% AND A 51.60% INCREASE IN GROSS PROFIT.

COSMOS HEALTH REPORTS Q2 2025 RESULTS; CONTINUES STRONG GROWTH WITH 11.7% REVENUE INCREASE; ON TRACK TO MEET PROFITABILITY TARGETS WITH GROSS PROFIT UP 53% TO $3.21M IN H1 2025

CHICAGO, AUG. 12, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. (COSMOS HEALTH OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, ANNOUNCED TODAY THAT IT HAS COMMENCED PURCHASES OF ETHEREUM (ETH), ADVANCING ITS DIGITAL ASSET TREASURY RESERVE STRATEGY. PURSUANT TO ITS FINANCING FACILITY OF UP TO $300 MILLION (THE FACILITY) WITH A U.S.-BASED INSTITUTIONAL INVESTOR, COSMOS HEALTH HAS COMPLETED ITS INITIAL $1 MILLION PURCHASE OF ETH.

COSMOS HEALTH MAKES INITIAL $1M ETHEREUM PURCHASE UNDER DIGITAL ASSET TREASURY STRATEGY

COSMOS HEALTH SECURES FINANCING OF UP TO $300 MILLION TO DEVELOP AN ETH-BACKED TREASURY, WITH REMAINING PROCEEDS FOR GROWTH AND GENERAL WORKING CAPITAL

COSMOS HEALTH SECURES UP TO $300 MILLION FINANCING FACILITY TO LAUNCH ETHEREUM TREASURY STRATEGY

CHICAGO, JUNE 24, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY'') (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP ENGAGED IN INNOVATIVE R&D, OWNER OF PROPRIETARY PHARMACEUTICAL AND NUTRACEUTICAL BRANDS, MANUFACTURER AND DISTRIBUTOR OF HEALTHCARE PRODUCTS, AND OPERATOR OF A TELEHEALTH PLATFORM, ANNOUNCED TODAY ITS ENTRY INTO THE U.S. MARKET AND THE LAUNCH OF U.S.-BASED MANUFACTURING THROUGH A STRATEGIC AGREEMENT WITH DOLCAS BIOTECH LLC (DOLCAS), A NEW JERSEY-BASED DEVELOPER AND MANUFACTURER OF CLINICALLY STUDIED NUTRACEUTICAL INGREDIENTS. COSMOS HEALTH IS SET TO COMMENCE PRODUCTION IN THE UNITED STATES AT GMP-CERTIFIED (GOOD MANUFACTURING PRACTICE) FACILITIES, MARKING A SIGNIFICANT MILESTONE IN THE COMPANY'S OPERATIONAL EXPANSION.

COSMOS HEALTH ENTERS U.S. MARKET WITH STRATEGIC MADE-IN-AMERICA MANUFACTURING, MITIGATING TARIFF RISKS; EXECUTES AGREEMENT WITH NEW JERSEY-BASED DOLCAS BIOTECH

Cosmos Health Inc.

COSM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Cosmos Health Inc.

COSM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

COSM